Market Cap
$768.5M
FTH
Faeth Therapeutics, Inc.
$28.35 ▲ +0.28%
Prev close $28.27Market cap$768.5M
ConsensusStrong Buy
12-mo target$56.67 (+99.9%)
▲ Bullish
Analyst conviction 9/10
Insider Buying Cluster (2 insiders)12 New Institutional Positions Biotech & Drug Discovery
Snapshot
The big-picture read on FTH right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (93%)
Inst. Holders
20 funds
Inst. Value
$137.0M
Inst. Activity
12 buys / 1 sells
Insider Activity
$1.2M buy / $0.00 sell
Insider Net $
$1.2M
SEC Reports
5
Price chart 30d -27.3%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 15, 2026 SEC Aug 4, 2026 SEC
Karen H. Vousden filed an initial statement of beneficial ownership (Form 3) with the SEC, reporting 42,631 shares of Fa
3 — Impact 2/10
Sep 15, 2026 short_interest_report
Short Interest: FTH up 20% to 1.3M shares
Settlement 2026-09-15 | Days to cover: 4.37 | ≈5.10% of shares outstanding (est.)
Sep 11, 2026 Insider
Aug 11, 2026 SEC Vousden Karen H was granted 25,000 shares
Director
Cambrian BioPharma Inc, a 10% stockholder of Faeth Therapeutics, filed a Form 144 notice of intent to sell 130,142 share
144 — Impact 5/10
Faeth Therapeutics (FTH) reported Q2 2026 financial results with a net loss of $16.0M ($2.84/share), compared to a net l
8-K — Impact 3/10
Jul 21, 2026 Insider
Parikh Anand Kiran was granted 398,018 shares
President and CEO
Jul 21, 2026 Insider
Craver Josiah was granted 30,824 shares
PAO
Jun 30, 2026 Inst.
Avoro Capital Advisors LLC — NEW
1,444,039 shares ($36.1M)
Analyst ratings buy % +9300.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
93% rate it Buy or better · 15 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 16, 2026 | Guggenheim | INITIATE | Buy | 52% |
| Sep 14, 2026 | LUCID CAPITAL MARKETS | INITIATE | Buy | 36% |
| Sep 9, 2026 | TD Cowen | INITIATE | Buy | 56% |
| Aug 21, 2026 | Needham | INITIATE | Buy | 50% |
| Aug 11, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 4, 2026 | Jones Trading | INITIATE | Buy | 51% |
| Jul 31, 2026 | Raymond James | INITIATE | Outperform | 54% |
| Jul 28, 2026 | Oppenheimer | INITIATE | Outperform | 52% |
| Jul 20, 2026 | Citizens | INITIATE | Market Outperform | 38% |
| Jul 16, 2026 | BTIG | REITERATE | Buy | 53% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% | |
| Aug 1, 2026 | 6 | 7 | 1 | 0 | 0 | 93% | |
| Jul 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% | |
| Jun 1, 2026 | 4 | 4 | 2 | 0 | 0 | 80% | |
| May 1, 2026 | 3 | 3 | 2 | 0 | 0 | 75% | |
| Apr 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Mar 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% |
Price targets
Where 12 covering analysts think FTH trades over the next 12 months.
$56.67 +99.9% upside Strong Buy
Current$28.35 Low$46.00 Median$56.00 High$70.00 12 analysts
$46.00$70.00
Analyst rating Strong Buy· 1.2/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
5 SEC filing reports analyzed · 0 bullish, 1 bearish, 0 mixed, 4 neutral · avg impact 3.6/10.
NEUTRAL32/10
Karen H. Vousden filed an initial statement of beneficial ownership (Form 3) with the SEC, reporting
Sep 15, 2026
BEARISH1445/10
Cambrian BioPharma Inc, a 10% stockholder of Faeth Therapeutics, filed a Form 144 notice of intent t
Aug 11, 2026
NEUTRAL8-K3/10
Faeth Therapeutics (FTH) reported Q2 2026 financial results with a net loss of $16.0M ($2.84/share),
Aug 4, 2026
NEUTRAL35/10
No summary provided
Jul 28, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 15, 2026
short_interest_report
Short Interest: FTH up 20% to 1.3M shares
Settlement 2026-09-15 | Days to cover: 4.37 | ≈5.10% of shares outstanding (est.)
Aug 31, 2026
short_interest_report
Short Interest: FTH up 33% to 1.1M shares
Settlement 2026-08-31 | Days to cover: 3.67 | ≈4.25% of shares outstanding (est.)
Aug 11, 2026
earnings_calendar
FTH Q2 2026 Earnings Scheduled — 2026-08-11
Aug 6, 2026
ftd
FTD: FTH — 456,691 shares ($11.2M) failed to deliver
Settlement: 20260806, Price: $24.59, FTD Value: $11,230,031.69, FAETH THERAPEUTICS INC COM NEW
Aug 5, 2026
ftd
FTD: FTH — 295,858 shares ($7.5M) failed to deliver
Settlement: 20260805, Price: $25.50, FTD Value: $7,544,379, FAETH THERAPEUTICS INC COM NEW
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.71 | $-0.77–$-0.66 | — | -8.3% | — | $0.0B | 2 |
| Next Q | $-0.79 | $-0.88–$-0.69 | — | -13.8% | — | $0.0B | 2 |
| Current FY | $-13.78 | $-15.58–$-11.98 | — | -15.0% | 1↑ 0↓ | $0.0B | 2 |
| Next FY | $-4.49 | $-4.96–$-4.02 | 67.4% | +9.5% | 1↑ 0↓ | $0.0B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.715 | — |
| 7d ago | $-0.660 | -0.055 |
| 30d ago | $-0.660 | -0.055 |
| 60d ago | $0.000 | -0.715 |
| 90d ago | $0.000 | -0.715 |
Institutional ownership
Which big funds own FTH (from quarterly 13F filings) and who is adding or trimming.
20 institutional holders with $137.0M total value (5,479,309 shares) as of 2026-Q2. Top holders: Avoro, BAKER, BALYASNY. Net buying activity: 12 institutions added/increased vs 1 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 1,444,039 | $36.1M | 26.4% | NEW |
| BAKER BROS. ADVISORS LP | 1,286,411 | $32.2M | 23.5% | NEW |
| BALYASNY ASSET MANAGEMENT L.P. | 1,042,198 | $26.1M | 19.0% | DOUBLED +6331.3% |
| RA CAPITAL MANAGEMENT, L.P. | 722,020 | $18.1M | 13.2% | NEW |
| FRANKLIN RESOURCES INC | 494,516 | $12.4M | 9.0% | — |
| MARSHALL WACE, LLP | 206,508 | $5.2M | 3.8% | DOUBLED +214.2% |
| Alyeska Investment Group, L.P. | 144,404 | $3.6M | 2.6% | — |
| UBS Group AG | 21,541 | $538.5K | 0.4% | DOUBLED +375.6% |
| RENAISSANCE TECHNOLOGIES LLC | 20,416 | $510.4K | 0.4% | TRIM -36.3% |
| JANE STREET GROUP, LLC | 20,117 | $502.9K | 0.4% | DOUBLED +126.7% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | NEW | — | 1,444,039 | — | $36.1M |
| BAKER BROS. ADVISORS LP | NEW | — | 1,286,411 | — | $32.2M |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | 16,205 | 1,042,198 | +6331.3% | $26.1M |
| RA CAPITAL MANAGEMENT, L.P. | NEW | — | 722,020 | — | $18.1M |
| MARSHALL WACE, LLP | DOUBLED | 65,730 | 206,508 | +214.2% | $5.2M |
| UBS Group AG | DOUBLED | 4,529 | 21,541 | +375.6% | $538.5K |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 32,041 | 20,416 | -36.3% | $510.4K |
| JANE STREET GROUP, LLC | DOUBLED | 8,872 | 20,117 | +126.7% | $502.9K |
| MORGAN STANLEY | ADD | 8,795 | 17,329 | +97.0% | $433.2K |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | 9,501 | 14,616 | +53.8% | $365.4K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
6 insiders, 37 transactions. Net $1.2M — $1.2M bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | Vousden Karen H | Director | AWARD | 25,000 | — | — |
| Jul 21, 2026 | Parikh Anand Kiran | President and CEO | AWARD | 398,018 | — | — |
| Jul 21, 2026 | Craver Josiah | PAO | AWARD | 30,824 | — | — |
| Jul 1, 2026 | STEPHENSON BRIAN C | Chief Financial Officer | BUY | 600 | $24.22 | $14.5K |
| Jul 1, 2026 | STEPHENSON BRIAN C | Chief Financial Officer | BUY | 4,400 | $23.40 | $103.0K |
| Jun 30, 2026 | STEPHENSON BRIAN C | Chief Financial Officer | BUY | 4,255 | $24.98 | $106.3K |
| Jun 30, 2026 | STEPHENSON BRIAN C | Chief Financial Officer | BUY | 1,638 | $23.88 | $39.1K |
| Jun 30, 2026 | STEPHENSON BRIAN C | Chief Financial Officer | BUY | 1,910 | $22.95 | $43.8K |
| Jun 29, 2026 | STEPHENSON BRIAN C | Chief Financial Officer | BUY | 831 | $23.34 | $19.4K |
| Jun 26, 2026 | STEPHENSON BRIAN C | Chief Financial Officer | BUY | 100 | $26.39 | $2.6K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for FTH.
Shares short
1,318,893
Settlement Sep 15, 2026
Change vs prior
+20.1%
Semi-monthly cycle
Days to cover
4.4
At avg daily volume
Of shares outstanding
≈5.1%
Estimate — not % of float
| Halted | Code | Reason | Status |
|---|---|---|---|
| Jul 15, 2026 | LUDP | Volatility Pause | Resumed |
All FTH filing & press-release reports (5)
- 3 reportSep 15, 2026
- 144 reportAug 11, 2026
- 8-K reportAug 4, 2026
- 3 reportJul 28, 2026
- CLUSTER reportJul 2, 2026